UV Spectrophotometricdetermination; absorbance wavelength of 242 +- 2nm; Medium-phosphate buffer, pH 6.8 (dissolution medium).RESULTSAtorvastatin film coated tablets a 20 mg were produced by wetgranulation method with the following composition: Calciumcarbonate powder, Lactose monohydrate, Celullose microcrystalline,Croscarmellose sodium, Povidone, Polyoxyethylene sorbitan fatty acidesters (Polysorbate 60), Silica colloidal anhydrous, Talc pharma grade,Magnesium stearate, and Opadry white 03F28342. Each batch of thefinished product was tested for dissolution. For each batch of the APIa Malvern Mastersizer report was provided by the manufacturer.Table 1 Comparative table of particle size of the crystalline Atorvastatincalcium API with percent dissolution of the film coated tablets*Data provided by the API manufacturer. Each value is a mean of 3measurements of the lot.Graph 1 Particle size distribution graph by Malvern Mastersizer of thelot AVK1BJJ51A**Data provided by the API manufacturer. The graph is representationof 3 measurements of the lot.DISCUSSION AND CONCLUSIONThe dissolution rate of atorvastatin calcium film coated tabletsdepends not only on the particle size but particle size distribution aswell. Especially important is the distribution of the particles in therange D(0.50)-D(0.90). The batches of the API with tight distributionD(0.50)-D(0.90) have higher dissolution rates and batches with widedistribution D(0.50)-D(0.90) have lower dissolution rates. REFERENCES1. Salam WA., Lupuleasa D.- Enhancement of solubility and dissolution rate ofdifferent forms of atorvastatin calcium in direct compression tablet formulas,Farmacia, 2009; 57, 3: 290-3002. Roth BD., Warner- Lambert Company.- Trans-6-[2-(3- or 4- carboxamido-substituted pyrrol-1-yl) alkyl]-4-hydroxypyran-2-one inhibitors of cholesterolsynthesis, United states patent 4,681,893, 19873. Briggs CA., et al, Warner- Lambert Company.- Crystalline [R- (R*,R*)]-2- (4-dfluorophenyl)-b,d-dihydroxy-5- (1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin), United states patent5,969,156, 19994. Leon Shargel L., Andrew B.C.Yu; Encyclopedia of Pharmaceutical Technology2002 BiopharmaceuticsVLIJANIE NA GOLEMINATA NA ChESTITsINA RASTVORLIVOSTA NA ATORVASTATINKALTsIUM TABLETIE. Adamova, L. Makraduli, R. Dameska, E.Ristevska, L. Ivcheska, Kh. Litovin, D. Dimova, A.Sekovanikj, M. Anevska, D. Lepchevska 1Replekfarm, Kozle 188, 1000 Skopje, R. MakedonijaVOVEDAtorvastatin e sintetski agens za regulatsija na lipidniot status,inkhibitor na 3-hydroxy-3- methyl-glutaryl-coenzyme A (HMG- CoA)reduktaza koja ja katalizira konverzijata na HMG-Co A vomevalonat-edna od pochetnite fazi vo biosintezata na kholesterol.Spored BCS pripagja na kategorija II - niska rastvorlivost, visokapermeabilnost. Toj e mnogu slabo rastvorliv vo voda, vo fosfatenpufer so pH= 7.4 i vo atsetonitril. Vo voden rastvor (pH <= 4)praktichno e nerastvorliv. Mozhe da postoi vo amorfna forma ivo povekje kristalni formi (I, II, III, IV...) [1]. Bioraspolozhivosta naatorvastatin-eden od kluchnite parametri za negovoto terapevtskodejstvo zavisi od negovata forma(amorfna, kristana ili smesa)upotrebena vo formulatsijata. Amorfnite formi na nekoi aktivnisupstantsii vo odnos na kristalnite formi pokazhuvaatvarijabilna stabilnost, bioraspolozhivost i rastvorlivost.Spored marketing avtorizatsijata od U.S. FDA za LipitorTM naWarner-Lambert, atorvastatinot bil pochetno sintetiziran voamorfna forma [2]. Vo nekoi ispituvanja se pokazha deka ovaaforma e khigroskopna i nestabilna vo prisustvo na kislorod.Podotsna vo Warner-Lambert e razviena postabilna kristalnaforma na atorvastatin. Zaradi podobrata stabilnost i podobraabsorptsija od GIT, vo trgovskata formulatsija na atorvastatin sekoristi kristalen atorvastatin [3]. Fizichkite formi na aktivnitesupstantsii-kristalna ili polimorfna; stepenot na khidratatsijaili solvatatsija; goleminata, oblikot na chestitsite idistributsijata na chestitsite spored golemina imaat znachitelnovlijanie na rastvorlivosta na aktivnata supstantsija i brzinata istepenot na absorptsija. So namaluvanje na goleminata na chestitsite266Makedonski farmatsevtski bilten 57 (dodatok), 2011FARMATsEVTSKA TEKhNOLOGIJA I BIOFARMATsIJAposter prezentatsiiPETTI KONGRES NA FARMATsIJATA SO MEGjUNARODNO UChESTVOse zgolemuva efektivnata povrshina na supstantsijata[4]. Soreduktsija na dimenzijata na chestitsite se zgolemuva absorptsijatana teshko rastvorlivite supstantsii preku zgolemuvanje na brzinatana rastvaranje [1]. TsELDa se ispita vlijanieto na goleminata na chestitsite i nivnatadistributsija spored golemina vrz brzinata na rastvaranje nakristalen atorvastatin kaltsium vo farmatsevtska formulatsijafilm-oblozheni tableti. Da se ispita dali osven polimorfnataforma, goleminata na chestitsite i nivnata distributsija sepodednakvo znachajni parametri za podobruvanje narastvorlivosta na teshko rastvorlivi supstantsii kakoatorvastatin kaltsium.MATERIJALI I METODIAtorvastatin kaltsium trikhidrat kristalen (Zydus Cadila HealtcareLtd. ); Test za rastvorlivost: spored Ph.Eur. 2.9.3; Aparat 2-veslo vofosfaten pufer so pH= 6.8, 900 ml; za vreme od 30 min i broj narotatsii od 75 rpm. Spetsifikatsija za rastvorlivost: Min. 80% (Q + 5%) rastvorenatorvastatin na film-oblozhena tableta, kako protsent oddeklariranata sodrzhina. UV spektrofotometrisko otchituvanje na242 +- 2nm vo istiot pufer. REZULTATIAtorvastatin film- oblozheni tableti od 20 mg so sostav: Calciumcarbonate powder, Lactose monohydrate, Celullose microcrystalline,Croscarmellose sodium, Povidone, Polyoxyethylene sorbitan fatty acidesters (Polysorbate 60), Silica colloidal anhydrous, Talc pharma grade,Magnesium stearate, and Opadry white 03F28342 se izraboteni sovlazhna granulatsija. Testirana e rastvorlivosta na sekojaproizvedena serija na gotov proizvod. Tabela 1 Komparativna tabela na golemina na chestitsi na kri -stalna aktivna supstantsija Atorvastatin kaltsium i rastvorlivostna film- oblozheni tableti * Podatotsi dobieni od proizvoditelot na aktivnata supstantsija.Sekoja vrednost e prosek od 3 merenja. Grafik 1 Grafik na distributsija na chetitsi po golemina (merenoso Malvern Mastersizer) na serija AVK1BJJ51AZAKLUChOKBrzinata na rastvorlivost na atorvastatin film-oblozhenitableti zavisi ne samo od goleminata na chestitsi tuku i od nivnatadistributsija spored golemina. Osobeno e znachajna distributsijatana chestitsi vo opsegot D(0.50)-D(0.90). Seriite na aktivnasupstantsija so tesna distributsija D(0.50)-D(0.90) imaat podobrarastvorlivost, a seriite so shiroka distributsija D(0.50)-D(0.90)imaat poniska rastvorlivost.LITERATURA1. Salam WA., Lupuleasa D.- Enhancement of solubility and dissolution rate ofdifferent forms of atorvastatin calcium in direct compression tablet formulas,Farmacia, 2009; 57, 3: 290-3002. Roth BD., Warner- Lambert Company.- Trans-6-[2-(3- or 4- carboxamido-substituted pyrrol-1-yl) alkyl]-4-hydroxypyran-2-one inhibitors of cholesterolsynthesis, United states patent 4,681,893, 19873. Briggs CA., et al, Warner- Lambert Company.- Crystalline [R- (R*,R*)]-2- (4-dfluorophenyl)-,-dihydroxy-5- (1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin), United states patent5,969,156, 19994. Leon Shargel L., Andrew B.C.Yu; Encyclopedia of Pharmaceutical Technology2002 Biopharmaceutics267Macedonian Pharmaceutical Bulletin 57 (suppl), 2011PHARMACEUTICAL TECHNOLOGY AND BIOPHARMACYposter presentationsFIFTH CONGRESS OF PHARMACY OF MACEDONIA WITH INTERNATIONAL PARTICIPATIONFORMULATION OF GASTRO-RESISTANTTABLETS WITH EUDRAGIT(r)Sonja Dimchevska, Packa Antovska, Bosilka Ste-fanova, Sonja UgarkovicResearch and Development, ALKALOID AD, Aleksandar Makedonski 12,1000 Skopje, Republic of MacedoniaPolymethacrylates (known under the name Eudragit(r)), are excipientswith different usage in the pharmaceutical industry. Their primary useis in the film-coating of solid dosage forms as film-coating polymerswith specific characteristics. Depending on the type of polymer used,films of different solubility characteristics can be produced. Also, poly-methacrylates are used in sustained release formulations, in tastemasking coatings, protective coatings for active substances sensitiveto humidity, oxygen and light. Still, most frequently polymethacry-lates are used in functional coatings for targeted release of drugs inthe gastro-intestinal tract (small intestine or colon) 1,2. SCOPETo formulate gastro-resistant tablets which contain active substancefor local action in the colon with Eudragit as film-forming polymer.The key to controlling the release of the drug is the pH-dependent dis-solution of the polymer in the film coating, which enables drug releasein specific section of the gastro-intestinal tract1. Since it is necessarythe polymer to dissolve when the tablet reaches the colon where pHis around 7, the most suitable for this purpose is poly(methyl acrylate,methyl metacrylate, methacrylic acid), which is commercially availableas 30% water dispersion.MATERIALS AND METHODSWater dispersion of polymethacrylates, Triethyl citrate, Glycerol mono-stearate, Polysorbate 80, pigment iron oxide yellow, Emulsion simeti-cone 30%, Talc, Opadry clear. During the film-coating process, polymethacrylates become sticky(tacky) and rubbery and there is possibility of agglomeration while pro-cessing. Therefore, addition of anti-tacking agents is necessary to min-imize this sticking tendency (talc, glycerol monostearate)1. During theformulation of the suspension for film-coating with Eudragit, the ac-cent was on overcoming the stickiness of the Eudragit and enablinggood and stable coating process. For that purpose, different formula-tions of the Eudragit suspension were made which had different anti-tacking agents in different concentrations. Film-coating was performed in conventional pan for film-coating. Theformulation with talc was rejected due to its sedimentation in thecoating suspension and decreased flow through the spray nozzle. For-mulations with glycerol monostearate enabled good process of film-coating without sticking and agglomeration of tablets. Thefilm-coated gastro-resistant tablets (formulation 2 and 3) compliedwith the pharmacopoeial test for disintegration of this type of tablets:tablets must not disintegrate in 0.1M HCl for 2 hours and should dis-integrate in 1.5 %w/v solution of sodium hydrogen carbonate for onehour 3. However, in-bulk storage of the film-coated tablets at roomtemperature for couple of weeks, showed agglomeration of tabletswith formulation 2, which was not the case with the tablets with big-ger concentration of glycerol monostearate as anti-tacking agent (For-mulation 3). Still, for providing better insurance that the coatedtablets will not stick to the blister nests during the product's shelf life,gastro-resistant tablets were further coated with another protectivelayer of film based on hydroxypropyl methylcellulose (Opadry clear). CONCLUSIONFilm-coated tablets with formulation 3 (10%w/w glycerol mono-stearate calculated on dry polymer substance) and additional protec-tive film-layer of Opadry clear showed good results. Tablets in blisterpackaging didn't show sticking tendency of the film-coating to blisternests, which indicates on appropriate selection of the type and con-centration of the anti-tacking agent. REFERENCES1. Eudragit(r) Application Guidelines, 11th edition, september 2009, EvonikIndustries2. R.C. Rowe, P. J. Sheskey, S. C. Owen, The Handbook of PharmaceuticalExcipients, Pharmaceutical Press and American Pharmacists Association (2006)3. British Pharmacopoeia 2011FORMULATsIJA NA GASTRO-REZISTENTNI TABLETI SO EUDRAGIT(r)Sonja Dimchevska, Patska Antovska, BosilkaStefanova, Sonja UgarkovikjIstrazhuvanje i razvoj, ALKALOID AD, Aleksandar Makedonski 12,1000 Skopje, Republika MakedonijaPolimetakrilatnite polimeri (poznati pod imeto EudragitO) seekstsipienti koi naogjaat razlichna primena vo farmatsevtskataindustrija. Nivnata najchesta primena e vo oblozhuvanjeto na tsvrstidozirani formi kako film-obrazuvachki polimeri so spetsifichnikarakteristiki. Zavisno od tipot na polimer, se dobivaat film-obvivki so razlichna rastvorlivost. Isto taka, polimetakrilatitese koristat i vo formulatsii so prodolzheno osloboduvanje, zamaskiranje na neprijaten vkus i miris, kako zashtitni filmovi kajaktivni supstantsii osetlivi na vlaga, kislorod i svetlina. Sepak,najchesto polimetakrilatite se koristat kako funktsionalnifilmovi za targetirano osloboduvanje vo gastro-intestinalniottrakt (tenkoto tsrevo ili kolonot) 1,2. TsELDa se formulira gastro-rezistentna tableta so aktivna supstan -tsija nameneta za lokalno dejstvo vo kolonot so upotreba na Eudra-git kako film-obrazuvachki polimer.